All News
Advice on Multi-Drug Failures in RA
What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.
Read Article
RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
Read Article
What Changed FDA's Mind About Ilaris for Gout?
The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed in the dozen years since the company's first attempt to gain app
Read Article
RA Associated Cancer Risk
A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.
Read Article
Machine Learning May Diagnose Psoriatic Arthritis Earlier
A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA).
Read Article
RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)
This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".
Read Article
Oral Surveillance Changes in Advanced Therapy Use in RA
The safety of tofacitinib and TNF inhibitors was studied in high risk rheumatoid arthritis (RA) patients in the ORAL Surveillance study, which culminated in an FDA warning in January 2021 on the cardiovascular, cancer and VTE risks associated with JAK inhibitor use.
Read Article
ICYMI: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions
The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Read Article
Hard Decisions in RA (9.1.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Read Article
FDA Approves Canakinumab for Gout Flares
The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response to NSAIDs or colchicine.
Read Article
2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
The American College of Rheumatology (ACR) and EULAR have combined efforts to establish an international multidisciplinary Steering Committee to develop classification criteria for the new antiphospholipid syndrome (APS) to be applied in observational studies and clinical trials.
Read Article
Biologic Adherence and Drug Survival in RA Patients
A real-world rheumatoid arthritis (RA) cohort study from Israel shows significant variability of drug survival using biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).
Read Article
ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions
The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Read Article
COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis
The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.
Read Article
Residual Disease in Controlled Axial Spondyloarthritis
Despite being in a state of remission or low disease activity state, in patients with axial spondyloarthritis, up to 42% may still have residual disease.
Read Article
Stable Safety Outcomes with Abatacept
The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns.
Read Article
The Adalimumab Biosimilar Glut
In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.
Read Article
Pizza and Rheumatoid Arthritis (8.11.2023)
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
Read Article
PRESTO Tool Predicts the Risk of Psoriatic Arthritis
In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that identif
Read Article
ACR Comments on US Healthcare Policy
The American College of Rheumatology (ACR) said it has already joined with hundreds of organizations to submit 26 health policy comment letters to federal officials this year—surpassing the 24 letters the College submitted in 2022.
Read Article